Vestal Point Capital, LP — ENLIVEN THERAPEUTICS INC ELVN: Quarterly 13F Position History
Vestal Point Capital, LP has reported ENLIVEN THERAPEUTICS INC (ELVN) on 4 13F-HR filings in Pactolio's tracked window, first appearing in Q2 2025. As of Q1 2026, the position is sized at 3,250,000 shares ($127.4M market value, 3.56% of the equity book). Quarter-over-quarter share count change: 580,000 (-15.1%) .
- 3,250,000Shares Held (Latest Filing)
- $127.4MReported Market Value (Latest Filing)
- 3.56%Portfolio Weight (% of 13F Equity Book)
- 580,000Quarter-over-Quarter Share Change
- +$68.4MQuarter-over-Quarter Value Change
- 3,830,000Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 4 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 3,250,000 | 580,000 | -15.1% | $127.4M | 3.56% | $39.20 |
| Q4 2025 | 3,830,000 | +2,670,000 | +230.2% | $59.0M | 2.16% | $15.40 |
| Q3 2025 | 1,160,000 | +910,000 | +364.0% | $23.7M | 1.08% | $20.47 |
| Q2 2025 | 250,000 | — | — | $5.0M | 0.26% | $20.06 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did Vestal Point Capital, LP first disclose a ELVN position in 13F-HR filings?
Vestal Point Capital, LP first reported ENLIVEN THERAPEUTICS INC (ELVN) on its 13F-HR filing for the period ending 2025-06-30 (Q2 2025). The position has appeared on 4 reported quarters within Pactolio's tracked window.
What was Vestal Point Capital, LP's most recent quarter-over-quarter share-count change in ELVN?
Between Q4 2025 and Q1 2026, Vestal Point Capital, LP reduced its ELVN position by 580,000 shares (-15.1%), leaving 3,250,000 shares at a market value of $127.4M.
Does the implied price-per-share represent Vestal Point Capital, LP's cost basis in ELVN?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.